On May 21, 2025, Waters Corporation announced that it acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. Wilson Sonsini Goodrich & Rosati advised Halo Labs on the transaction.

Halo Labs' proprietary Aura™ platform offers advanced particle analysis that complements Waters' existing light scattering detection solutions. This technology is particularly beneficial for characterizing impurities in CAR T-cell therapies, which are currently undetectable by standard methods.

The Wilson Sonsini team that advised Halo Labs on the transaction includes:

Corporate
Brian Appel
Roy Argand
Esther Lim

Employee Benefits and Compensation
Michael Klippert
Gregory Hughes
Kristen Stidham

Employment Litigation
Jason Storck
Joseph Horne
Kelsey Sutton

Real Estate
Susan Reinstra
Martin Sul
Alex Corluyan

FDA Regulatory
Eva Yin
Jonathan Trinh

Data, Privacy, and Cybersecurity
Matt Staples
Michael O’Brien
Chany Kim

Tax
Myra Sutanto Shen
Rob Sherrill

Technology Transactions
Alex Key
Aleks Vitomirov
Kimberly Parry

For more information, please see Waters' news release.